34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial

Susana Banerjee, A. Leary, J.R. Stewart, M. Dewan, S. Lheureux, A.R. Clamp, I.L. Ray-Coquard, F. Selle, C. Gourley, R.M. Glasspool, R. Bowen, A. Attygalle, K. Vroobel, N. Tunariu, K. Wilkinson, C. Toms, R. Natrajan, J. Bliss, C. Lord, N. Porta